Global Tuberculosis Cases Reach 10.7 Million, Demanding New Solutions
Tuberculosis remains a significant global health threat, with millions affected and calls for innovative solutions to combat the disease.

Tuberculosis (TB) continues to be a major global health issue, with approximately 10.7 million cases reported and 1.23 million deaths attributed to it in 2024, according to the World Health Organization (WHO).
Dr. Ludoviko Zirimenya, a former palliative care physician, discussed the complications TB poses, particularly for patients also living with HIV. He emphasized the need for improved prevention methods, saying, “It is essential that we treat tuberculosis not just as a medical issue, but as a social one.”
The BCG vaccine, the most commonly used preventive measure against TB, has not changed significantly in over a century. Its effectiveness varies widely, leaving many individuals vulnerable to the disease. Experts believe that enhancing existing vaccination efforts is critical.
Current strategies are inadequate, leading health officials to advocate for innovative approaches to tackle TB in various populations, particularly in low and middle-income countries. Research is ongoing for next-generation TB vaccines, which could play a crucial role in addressing the issue. According to a report by Treatment Action Group, there are 14 vaccine candidates under clinical development, but translating research success into public health effectiveness requires sustained investment and equitable access.
Strengthening healthcare systems is considered vital for improving access to diagnosis and treatment. Community engagement and education about TB are essential in raising awareness and dispelling common misconceptions about the disease. Various stakeholders emphasize that addressing tuberculosis requires a comprehensive approach that looks beyond medical solutions to include social and systemic factors.
The Clinton Health Access Initiative reported that while the BCG vaccine is effective for young children, its protection diminishes after age five, and there are limited options for older populations. New TB prevention tools, once approved, might be available in low and middle-income countries within the next five years.
Experts stress that improved healthcare delivery, better access to preventive treatments, and innovative research will be key in reducing TB cases and fatalities moving forward.

